Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica.

Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica.

Human papillomavirus (HPV) infection, particularly with type 16, causes a growing fraction of oropharyngeal cancers, whose incidence is increasing, mainly in developed countries. In a double-blind controlled trial conducted to investigate vaccine efficacy (VE) of the bivalent HPV 16/18 vaccine again...

Full description

Bibliographic Details
Main Authors: Rolando Herrero, Wim Quint, Allan Hildesheim, Paula Gonzalez, Linda Struijk, Hormuzd A Katki, Carolina Porras, Mark Schiffman, Ana Cecilia Rodriguez, Diane Solomon, Silvia Jimenez, John T Schiller, Douglas R Lowy, Leen-Jan van Doorn, Sholom Wacholder, Aimée R Kreimer, CVT Vaccine Group
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3714284?pdf=render

Internet

http://europepmc.org/articles/PMC3714284?pdf=render

Similar Items